

OFFICE OF THE GENERAL COUNSEL  
Nevada State Board of Medical Examiners  
9600 Gateway Drive  
Reno, Nevada 89521  
(775) 688-2559

BEFORE THE BOARD OF MEDICAL EXAMINERS  
OF THE STATE OF NEVADA

\* \* \* \* \*

In the Matter of Charges and  
Complaint Against:  
LUKE ST. JOHN CESARETTI, M.D.,  
Respondent.

Case No. 21-7235-1

FILED

FEB 17 2022

NEVADA STATE BOARD OF  
MEDICAL EXAMINERS

By: 

FIRST AMENDED COMPLAINT

The Investigative Committee<sup>1</sup> (IC) of the Nevada State Board of Medical Examiners (Board), by and through Ian J. Cumings, J.D., Deputy General Counsel and attorney for the IC, having a reasonable basis to believe that Luke St. John Cesaretti, M.D., (Respondent) violated the provisions of Nevada Revised Statutes (NRS) Chapter 630 and Nevada Administrative Code (NAC) Chapter 630 (collectively, the Medical Practice Act), hereby issues its Complaint, stating the IC's charges and allegations as follows:

1. Respondent was at all times relative to this Complaint, a physician licensed to practice medicine in the State of Nevada (License No. 6238). Respondent was originally licensed by the Board on June 8, 1991.

**A. RESPONDENT'S TREATMENT OF PATIENT A**

2. Patient A was a 74-year-old female when she presented to Respondent during the events relevant to this complaint. Patient A's true identity is not disclosed herein to protect her privacy, but was disclosed in the Patient Designation served upon Respondent along with a copy of the original Complaint.

3. On February 22, 2017, Patient A had an initial abdominal ultrasound which indicated a clear two (2) cm mass in the mid-body of her pancreas.

<sup>1</sup> The Investigative Committee of the Nevada State Board of Medical Examiners, at the time this formal Complaint was authorized for filing, was composed of Board members, Chairman Rachakonda D. Prabhu, M.D., Victor M. Muro, M.D., and April Mastrolucca.

1           4.       On March 10, 2017, Patient A underwent further evaluation with a CT scan of the  
2 abdomen. The reading radiologist compared the CT with the previous abnormal ultrasound. The  
3 report described a dilated pancreatic duct in the body and tail with atrophy of the tail, but did not  
4 discuss the mass clearly identified on the ultrasound. The pancreatic mass was noted in the  
5 “Clinical History” portion of the Report. Patient A was recommended for further evaluation with  
6 a multiphase MRI out of concern for the abnormal findings on the CT.

7           5.       On March 16, 2017, Patient A presented to Respondent for an MRI due to the  
8 suspicious mass on her pancreas.

9           6.       In the Respondent’s records, he noted that Patient A had a history of an abnormal  
10 pancreas on the March 10, 2017, CT report. Respondent failed to acknowledge the pancreatic  
11 mass noted on the CT report, and made no attempt to obtain Patient A’s prior abnormal  
12 examinations.

13           7.       Respondent failed to review images from Patient A’s February 22, 2017,  
14 ultrasound, and the March 10, 2017, CT scan prior to his interpretation of Patient A’s MRI.  
15 Respondent based his comparison solely on the report of the March 10, 2017, CT scan.

16           8.       Notwithstanding this, the Respondent found that “no pancreatic masses are  
17 discernable” from his interpretation of Patient A’s MRI. Respondent noted a dilated pancreatic  
18 duct and atrophy of the pancreas at the level of ductal dilatation.

19           9.       Within the “Impression” portion of the MRI report, Respondent stated the ductal  
20 dilation could be either developmental or possibly related to a stricture of the duct proximal to the  
21 dilated portion. Respondent failed to specify in Patient A’s medical records, the importance of the  
22 findings and the relationship these findings have to the diagnosis of pancreatic ductal  
23 adenocarcinoma. Specifically, the dilated pancreatic duct indicated a high risk for an underlying  
24 pancreatic cancer. The association with the pancreatic atrophy is another indicator of Patient A's  
25 high risk for underlying cancer which the Respondent failed to alert Patient A’s referring  
26 physician to.

27       ///

28       ///

1 10. On April 7, 2017, Patient A obtained a second opinion, underwent an EUS guided  
 2 fine needle aspiration biopsy. The results of the endoscopic procedure were a finding of  
 3 malignant cells present, consistent with adenocarcinoma and metastatic adenocarcinoma.

4 **COUNT I**

5 **NRS 630.301(4) - Malpractice**

6 5. All the allegations contained in the above paragraphs are hereby incorporated by  
 7 reference as though fully set forth herein.

8 6. NRS 630.301(4) provides that malpractice of a physician is grounds for initiating  
 9 disciplinary action against a licensee.

10 7. NAC 630.040 defines malpractice as the failure of a physician, in treating a patient,  
 11 to use the reasonable care, skill, or knowledge ordinarily used under similar circumstances.

12 8. As demonstrated by, but not limited to, the above-outlined facts, Respondent failed  
 13 to use the reasonable care, skill or knowledge ordinarily used under similar circumstances when  
 14 he chose not to obtain Patient A’s previous exams, failed to identify the cancerous mass in  
 15 Patient A’s pancreas, and failed to alert the referring physician to the gravity of the findings he  
 16 described in the MRI report.

17 9. By reason of the foregoing, Respondent is subject to discipline by the Board as  
 18 provided in NRS 630.352.

19 **COUNT II**

20 **NRS 630.3062(1) - Failure to Maintain Proper Medical Records**

21 10. All the allegations contained in the above paragraphs are hereby incorporated by  
 22 reference as though fully set forth herein.

23 11. NRS 630.3062(1) provides that the “failure to maintain timely, legible, accurate,  
 24 and complete medical records relating to the diagnosis, treatment and care of a patient” constitutes  
 25 grounds for initiating discipline against a licensee.

26 12. Respondent failed to maintain proper medical records relating to the diagnosis,  
 27 treatment, and care of Patient A, by unconcernedly mentioning a possible developmental lesion on  
 28 the MRI report and failing to highlight the potential unacceptable high level of risk of pancreatic

1 carcinoma for a patient who had two (2) abnormal imaging studies and showed a pancreatic mass  
2 on the February 22, 2017, ultrasound.

3 13. By reason of the foregoing, Respondent is subject to discipline by the Board as  
4 provided in NRS 630.352.

5 **WHEREFORE**, the Investigative Committee prays:

6 1. That the Board give Respondent notice of the charges herein against him and give  
7 him notice that he may file an answer to the Complaint herein as set forth in NRS 630.339(2)  
8 within twenty (20) days of service of the Complaint.

9 2. That the Board set a time and place for a formal hearing after holding an Early  
10 Case Conference pursuant to NRS 630.339(3).

11 3. That the Board determine what sanctions to impose if it determines there has been  
12 a violation(s) of the Medical Practice Act committed by Respondent.

13 4. That the Board award fees and costs for the investigation and prosecution of this  
14 matter as outlined in NRS 622.400.

15 5. That the Board make, issue, and serve on Respondent its findings of fact,  
16 conclusions of law and order, in writing, that includes the sanctions imposed; and

17 6. That the Board take such other and further action as may be just and proper in these  
18 premises.

19 DATED this 17th day of February, 2022.

20 INVESTIGATIVE COMMITTEE OF THE  
21 NEVADA STATE BOARD OF MEDICAL EXAMINERS

22 By: \_\_\_\_\_

23 IAN J. CUMINGS, J.D.  
24 Deputy General Counsel  
25 9600 Gateway Drive  
26 Reno, NV 89521  
27 Tel: (775) 688-2559  
28 Email: [icummings@medboard.nv.gov](mailto:icummings@medboard.nv.gov)  
*Attorney for the Investigative Committee*

